Conformational Clamping by a Membrane Ligand Activates the EphA2 Receptor

Area of Science:

• Molecular biology
• Biophysics
• Cancer research

Background:

• The EphA2 receptor is a crucial target for cancer treatment, as its activation inhibits metastasis and tumor progression.
• TYPE7 peptide activates EphA2 via a novel mechanism involving its transmembrane (TM) domain, but the activation process is not fully understood.

Purpose of the Study:

• To elucidate the molecular mechanism by which the TYPE7 peptide activates the EphA2 receptor.
• To identify the specific binding motif and sequence requirements of TYPE7 for EphA2 activation.
• To understand the structural basis of EphA2 activation by transmembrane ligands.

Main Methods:

• Systematic sequence alteration of the TYPE7 peptide.
• Biophysical assays to characterize peptide-receptor interactions.
• Cell migration assays to assess functional activity.
• Mutational screening of the EphA2 transmembrane domain.
• Molecular dynamics simulations.

Main Results:

• Identification of a new, potent peptide variant through sequence modification.
• Determination of the helical interface mediating EphA2 transmembrane domain dimerization.
• Elucidation of the molecular mechanism: TYPE7 acts as a molecular clamp around the EphA2 TM dimer.
• Evidence that this binding mode stabilizes the active conformation of EphA2.

Conclusions:

• The TYPE7 peptide activates EphA2 by clamping its transmembrane dimer, stabilizing an active conformation.
• This study reveals the mechanism of EphA2 activation by transmembrane ligands.
• Findings provide insights into the design principles for novel transmembrane receptor-activating ligands.